Epigenetics market – new analysis showing you technological trends and sales forecasts
Do you want to find sales potentials of epigenetic technologies, diagnostics and medicines? Now get the latest analysis for that industry. There you explore developments (R&D), results, opportunities, trends and revenue forecasts.
Visiongain’s updated report shows you what’s possible for those drugs, diagnostic tests and related technology. Avoid missing out in data. Instead find progress in that industry and market, discovering expected advances and sales rises. See now how you can gain.
Assess technologies, products and services, benefiting your reputation for technological, medical and commercial insight. Read on, then, to explore that market and see its potential.
Forecasts and other information showing technical, clinical and business prospects
That new study gives you sales predictions to 2024 at overall world market, submarket, product and national level. See what the future holds for that emerging industry. For epigenetics you investigate where demand, opportunity and money lie.
Epigenetic uses hold great potential for diagnosing and treating diseases, including cancer.
There hear what’s possible. And avoid struggles to find information. Besides giving revenue predictions, our analysis shows historical results, growth rates and market shares.
In that work you discover 72 tables, 57 charts and an interview. There help your research, analyses and decisions, also benefiting your influence and staying ahead.
And the following sections explain what our new investigation gives.
World market and its segments – what revenues possible from 2014 to 2024?
What’s the commercial potential of epigenetics? Find in our report overall world revenue to 2024 for those products and technologies.
Also find individual revenue predictions to 2024 for three epigenetic submarkets at world level:
• Therapies
• Technologies for research
• Diagnostics
What’re the secrets of progress? There you assess outlooks for trade expansion, hearing where you could benefit. That work investigates products, uses and rising sales. You find commercial prospects.
That study also predicts and discusses leading epigenetic medicines’ sales potentials.
Revenue predictions for leading drugs and expected therapies
Our study forecasts revenues of top brands – four leading agents and two therapies awaiting launch. There you see individual revenue forecasts to 2024 for these products:
• Vidaza
• Dacogen
• Zolinza
• Istodax
And you gain predictions for these expected treatments:
• Beleodaq
• Faridak
There you explore drugs and years with highest predicted sales. Also you examine competitors. You see what’s happening there, understanding, challenges, trends and outlooks.
For that overall market, the report also shows geographical revenue predictions.
Sales in leading national markets – what outlooks for epigenetics?
Advances in pharmaceuticals, biotechnology and healthcare expand use of epigenetic services and products. See their prospects in developed and developing regions.
Our analyses show you individual revenue forecasts to 2024 for eight national markets and two regions:
• United States (US)
• Japan
• Canada
• Germany, France, UK, Italy and Spain (EU5), also with EU regional prediction
• Brazil, Russia, India and China (BRIC nations, grouped analysis).
There you find countries with highest revenues, demand and potential sales. Explore progress, needs and opportunities, seeing how you can gain. The study explains, helping you stay ahead.
Also how do events, challenges and advances in technology affect that industry and market? Our work shows you, discussing progress, policies and trends.
Strengths, challenges and events – what affects epigenetics?
The report explains issues, events and research and development (R&D) affecting that industry and market from 2014, including these forces:
• Uses for epigenetics in cancer, inherited disorders and neurological diseases
• DNA methlytransferase (DNMT) inhibition
• Histone deacetylase (HDAC) inhibitors
• Drug discovery and development using epigenetics
• Bisulphite screening for DNA methylation.
And you explore these influences and opportunities, among others:
• Chromatin immunoprecipitation (ChIP) for histone modification
• Chemogenic approaches to spatiotemporal regulation of HDAC activity
• Lysine pathways and acetylation-independent mechanisms
• DNMT inhibition and targeting other epigenetic enzymes
• Applications of genomics, proteomics and metabolomics
• Targeting orphan diseases and subpopulations – personalised and stratified medicine.
You explore what progress, trends and prospects mean. And you discover what benefits and restrains companies, affecting commercial performance. So what does the future hold?
Epigenetics – leading companies and 2018 market value
From 2014, applications of epigenetics hold great potential for investments, technological advances and sales. What happens next?
Our new report predicts the world market for those products and technologies will reach $4,279m in 2018, with high further sales growth to 2024.
There you also see what organisations shape that industry:
• Celgene
• Eisai
• Roche
• Janssen-Cilag
• Otsuka Pharmaceuticals
• Merck & Co.
You also assess activities of these firms:
• TopoTarget
• Syndax Pharmaceuticals
• MDxHealth
• Epigenomics
• Life Technologies
• Qiagen, 4SC, EMD Millipore, Orion Genomics, DiscoveRx, EpiTherapeutics and others.
R&D in that industry holds strengths. And from 2014 there will arise many opportunities. From this decade onwards, patients, payers and companies will benefit. See how.
Ways Epigenetic R&D, Therapies and Diagnostics: Industry and Market Prospects 2014-2024 helps
In three main ways our investigation helps your work:
• Revenues to 2024 at overall world level, for 3 submarkets and 6 products – assess outlooks for development, production, marketing and sales
• Forecasts to 2024 for eight national markets and two regions – investigate developed and developing countries for revenues and sales expansion
• Prospects for established competitors, rising companies and new entrants – explore products, R&D, opinions, and outlooks for success.
Knowledge there found nowhere else, benefiting your research, analyses and plans
Our work gives independent analysis. There you receive competitive intelligence found only in that report, seeing where business prospects are most rewarding.
With that investigation you’re less likely to fall behind in data or miss opportunity. Discover there how you can benefit your information searches, analyses and decisions. Also find how you could save time and gain in authority.
Our new study is for everyone assessing the present and future of epigenetics. Your choosing that analysis shows you results, trends, opportunities and sales predictions. So discover potential gains by getting that report here now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Epigenetic Therapies, Technologies and Diagnostics: World Market Review
1.2 Global Epigenetics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Main Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methods of Research and Analysis
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Introduction to Epigenetics and Uses in Pharma
2.1 How is Epigenetics Defined?
2.1.1 Epigenetic Mechanisms
2.1.2 A Brief History of Epigenetic Research
2.2 The Links between Epigenetics and Disease
2.2.1 The Role of Lifestyle in Epigenetics
2.2.2 Epigenetics and Cancer
2.2.3 Epigenetics in Inherited Disorders
2.2.4 Epigenetics in Neurological Diseases
2.3 Epigenetics in Disease Diagnosis
2.3.1 Diagnosing for Breast Cancer
2.3.2 Colorectal Cancer: The Importance of Early Diagnosis
2.3.3 Diagnostics for Lung Cancer: Difficulty in Accessing Samples
2.3.4 Diagnostics for Prostate Cancer
2.4 The Use of Epigenetics in Treating Diseases
2.4.1 DNA Methlytransferase (DNMT) Inhibitors
2.4.1.1 Myelodysplastic Syndrome (MDS)
2.4.2 Histone Deacetylase (HDAC) Inhibitors
2.4.2.1 Cutaneous T Cell Lymphoma (CTCL)
2.4.2.2 Peripheral T Cell Lymphoma (PTCL)
2.5 Drug Discovery and Development Tools Using Epigenetics
2.5.1 Bisulphite Screening for DNA Methylation
2.5.2 Chromatin Immunoprecipitation (ChIP) for Histone Modification
3. The Global Epigenetic Therapies, Technologies and Diagnostics Market 2014-2024
3.1 The Global Epigenetic Therapies, Technologies and Diagnostics Market in 2013
3.1.1 Leading Segments of the Market in 2013
3.2 The Epigenetic Therapies, Technologies and Diagnostics Global Market 2014-2024
3.2.1 The Epigenetic Therapies, Technologies and Diagnostics Global Market: Revenue Forecasts 2014-2024
3.2.2 What Will Expedite the Growth of Epigenetic Therapies, Technologies and Diagnostics Market?
3.2.3 Increase in Epigenetic Diagnostics Market Share 2014-2024
3.3 Epigenetic Therapies Submarket 2014-2024
3.3.1 Epigenetic Therapies Submarket: Revenue Forecast 2014-2024
3.3.2 Rising Importance of Epigenetic Therapies Revenue 2014-2024
3.4 Epigenetic Technologies Submarket 2014-2024
3.4.1 Epigenetic Technologies Submarket: Revenue Forecast 2014-2024
3.4.2 Epigenetic Technologies Submarket: Drivers and Restraints 2014-2024
3.5 Epigenetic Diagnostics Submarket 2014-2024
3.5.1 Epigenetic Diagnostics Submarket: Revenue Forecast 2014-2024
3.5.2 Growth Driving Factor: New Product Launches 2014-2024
4. Leading National Epigenetic Therapies, Technologies and Diagnostics Markets 2014-2024
4.1 Leading National Markets for Epigenetic Therapies, Technologies and Diagnostics 2013
4.2 Leading National Markets: Revenue Forecasts 2014-2024
4.2.1 Global Market Will Be Dominated by the Western Countries 2014-2024
4.3 The Northern American Market 2014-2024
4.3.1 The US: The World’s Largest Market for the Epigenetic Therapies, Technologies and Diagnostics 2014-2024
4.3.2 Canada: Revenue Forecast 2014-2024
4.4 European Union (EU) Epigenetics Market: Revenues 2013
4.4.1 Leading National Markets in EU: Revenue Forecasts 2014-2024
4.4.2 Germany: Revenue Forecast 2014-2024
4.4.3 The UK: A Leading Country for Epigenetic Research
4.5 Japanese Market: Increased Interest in Epigenetics
4.6 Epigenetics in Emerging National Markets
4.6.1 BRIC Nations: Positive Growth Expected in Epigenetic Therapies, Technologies and Diagnostics Markets 2014-2024
5. Epigenetic Therapies Market 2014-2024
5.1 The Future of the Epigenetic Therapies Market 2014-2024
5.2 Vidaza (Celgene Co. / Nippon Shinyaku): The First Therapy in the Epigenetic Market
5.2.1 Vidaza: Leading Epigenetic Therapy 2004-2012
5.2.2 How Was Vidaza Affected by Patent Expiry?
5.2.3 Will Oral Azacitidine and Combination Therapy Stimulate Vidaza Growth?
5.2.4 Vidaza: Revenue Forecast 2014-2024
5.3 Dacogen (Eisai/ Janssen-Cilag/ Otsuka Pharmaceutical Co.)
5.3.1 Dacogen: Historical Revenue Performance 2006-2012
5.3.2 EU Approval and Combination Therapy to Drive Sales Growth?
5.3.3 Will Oral Azacitidine and Combination Therapy Drive Vidaza Growth?
5.3.4 Dacogen: Revenue Forecast 2014-2024
5.4 Zolinza (Merck & Co./ Taiho Pharmaceutical)
5.4.1 Zolinza for Multiple Myeloma Treatment
5.4.2 Zolinza Revenue Forecast 2014-2024
5.5 Istodax: Second Epigenetic Drug by Celgene Co.
5.5.1 Istodax: Strong Revenue Growth 2010-2011
5.5.2 International Market Approvals to Drive Growth?
5.5.3 Istodax: Revenue Forecast 2014-2024
5.6 Epigenetic Therapy Market 2013: Rich Pipeline for HDAC Inhibitors
5.6.1 Beleodaq (TopoTarget/ Spectrum Pharmaceuticals): A Novel HDAC Inhibitor
5.6.2 Faridak (Novartis): Treatment for Velcade-Refractory Multiple Myeloma
5.6.3 Entinostat (Syndax Pharmaceuticals, Inc.): Breast and Lung Cancer
5.6.4 Resminostat (4SC/ Yakult Honsha Co.): Hepatocellular Carcinoma
5.6.5 Pracinostat (MEI Pharma): Treatment for MDS and AML
5.6.6 Mocetinostat: Initiatives of Mirati Therapeutics to Drive Development
5.6.7 Quisinostat (Janssen Pharmaceutica, NV/ NewVac LLC)
5.6.8 Rocilinostat (Acetylon Pharmaceuticals): One of Celgene’s Keen Interest
5.6.9 CHR-3396 (Chroma Therapeutics)
5.6.10 Givinostat (Italfarmaco): Chronic Myeloproliferative Neoplasms and Duchenne Muscular Dystrophy
5.6.11 Shape (TetraLogic Pharmaceuticals): The First Topical HDAC inhibitor for CTCL
5.6.12 FRM-0334 (Forum Pharmaceuticals Inc): Neurodegenerative Diseases
5.6.13 4SC-202: Second Epigenetic Drug by 4SC Has Potential for Wider Indications
5.6.14 Tefinostat (Chroma Therapeutics): Haematological Cancer
5.6.15 CDX10 (Celleron Therapeutics): Part of Personalised Cancer Treatment Trial
5.6.16 RG2833 (The Scripps Research Institute): Friedreich’s Ataxia
5.6.17 Abexinostat (Pharmacyclics)
5.7 New Discoveries in the Field of HDAC 2013
5.7.1 Chemogenic Approaches to Spatiotemporal Regulation of HDAC Activity
5.7.2 Novel Lysine Pathways and Acetylation-Independent Mechanisms of HDACs
5.7.3 HDAC Inhibitor: Treatment of Pathological Muscle Remodelling
5.7.4 Design of Class I Isoform Selective Inhibitors for Use in Metabolic Indications
5.7.5 Zinc Binding Groups Inhibit Class IIa HDAC and Alters Immune Responses
5.8 DNMT Inhibitor R&D Pipeline 2013
5.8.1 SGI-110 (Otsuka Pharmaceuticals): A Second Generation DNMT Inhibitor
5.8.2 FdCyd (National Cancer Institute): Solid Tumours
5.8.3 Hydralazine: Being Tested in 23 Clinical Trials
5.8.4 MG98 (Mirati Therapeutics)
5.8.5 CP-4200: A Second Generation Vidaza
5.8.6 RX3117 (Rexahn Pharmaceuticals)
5.9 Pipeline Treatments Targeting Other Epigenetic Enzymes 2013
5.9.1 EPZ-5676 (Epizyme Inc./ Celgene Co.): The First Clinical-Stage HMT Inhibitor
5.9.2 EPZ-5676 (Epizyme Inc./ Eisai): The Second Clinical-Stage HMT Inhibitor
5.9.3 ORY-1001(Roche): Orphan Drug Status in Early Stage AML
5.9.4 SP-2528 (Salarius Pharmaceuticals)
5.9.5 RVX-208 (Resverlogix): Advancing BET Protein Inhibitors
5.10 MiRNA Therapy Pipeline 2013
5.10.1 Miravirsen (Santaris Pharma A/S): The First miRNA Therapy to Enter Human Clinical Trial
5.10.2 MRX34 (Mirna Therapeutics)
5.10.3 Collaborations of Regulus Therapeutics with Big Pharma Players
5.11 Leading Epigenetic Therapy Manufacturers and Developers
5.11.1 Celgene: Market Leader in 2013
5.11.2 Eisai
5.11.3 Janssen-Cilag
5.11.4 Otsuka Pharmaceuticals
5.11.5 Merck & Co.
5.11.6 TopoTarget to Merge with BioAlliance Pharma SA
5.11.7 Syndax Pharmaceuticals
5.11.8 4SC
5.11.9 Curis: Focusing on Multi-Targeted Treatments
5.11.10 CellCentric: Collaborating with Big Pharma for Drug Development
5.11.11 Constellation Pharmaceuticals
5.11.12 EpiTherapeutics
5.11.13 Epizyme: Signed Multiple Collaboration Agreements with Big Pharma
5.11.14 IkerChem: HDAC and DNMT Inhibitors in Cancer and CNS Disorders
5.11.15 Karus Therapeutics: HDAC Inhibitors for Inflammatory Diseases and Cancer
6. Epigenetic Technologies: Markets 2014-2024
6.1 Epigenetic Technologies and Services Market 2014-2024
6.1.1 Should Epigenetic Discovery and Analysis Be Outsourced?
6.2 Next Generation Sequencing (NGS)
6.2.1 Higher Speed and Reduced Costs for Epigenetic Research
6.2.2 Are Current Bioinformatic Programmes a Setback?
6.2.3 Single Molecule Sequencing to Compete with NGS
6.3 The Future of Chromatin Immunoprecipitation
6.3.1 ChIP-Seq
6.4 Future Developments in Bisulphite Screening
6.4.1 Importance of Techniques to Distinguish 5hmC
6.5 High Throughput Screening
6.6 Leading Providers of Epigenetics Technologies 2013
6.6.1 Active Motif
6.6.2 Measurement Tools for Epigenetic Research by Agilent Technologies
6.6.3 Diagenode: Best –In-Class Methyl Binding Domain Based Kit
6.6.4 DiscoveRx
6.6.5 EMD Millipore
6.6.6 Epigenetek: Specialist in Epigenetic Technologies
6.6.7 Epiontis: Assessing Purity in Regenerative Medicine Products
6.6.8 Life Technologies: Reducing NGS Process Cost
6.6.9 Qiagen: Epigenetic Technologies and Diagnostics
6.6.10 Roche
7. Epigenetic Diagnostics Market 2014-2024
7.1 Development of the Epigenetic Diagnostics Market 2014-2024
7.1.1 LDTs vs. IVDs: Two Diagnostics Development Strategies
7.2 Epigenetic Diagnostics Market 2013
7.2.1 Epi proColon 2.0 (Epigenomics)
7.2.2 ColoVantage (Quest Diagnostics)
7.2.3 Septin9 LDT (ARUP Laboratories)
7.2.4 ColoSure (LabCorp)
7.2.5 ConfirmMDx for Prostate Cancer
7.2.6 Gene Methylation in Prostate Cancer (LabCorp)
7.2.7 Epi proLung (Epigenomics)
7.2.8 MGMT Gene Methylation Assay (LabCorp)
7.2.9 PredictMDx (MDxHealth): Brain Cancer
7.2.10 Bladder Cancer Testing with CertNDx (Physician’s Choice Laboratory Services)
7.3 Epigenetic Diagnostics R&D Pipeline 2013
7.3.1 The Future of Colorectal Cancer Testing
7.3.1.1 Cologuard: Improved Sensitivity
7.3.1.2 Orion Colorectal Cancer Risk Test (Orion Genomics)
7.3.2 Pipeline of Prognostic Tools for Prostate Cancer
7.3.3 Lung Cancer
7.3.3.1 Lung Cancer Screening Test (Orion Genomics)
7.3.3.2 ConfirmMDx and InformMDx (MDxHealth)
7.3.4 The Future of Bladder Cancer Testing
7.3.4.1 Bladder Cancer Screening Test (Orion Genomics)
7.3.5 Other Cancer Tests Pipeline 2013
7.3.5.1 Pancreatic Cancer Prognostic Test (PrognosticDx Health)
7.4 Leading Epigenetic Diagnostic Developers 2013
7.4.1Epigenomics: Multiple Tests Marketed in the EU
7.4.1.1 Positive Revenue Growth 2012-2013
7.4.2 Exact Sciences: Colorectal Cancer Screening
7.4.3 MDxHealth: Targeting the US Diagnostics Markets
7.4.3.1 Strong Revenue Growth 2009-2013
7.4.4 Orion Genomics: More than 100 Markers Have Been Discovered
7.4.5 Physician’s Choice Laboratory Services (PCLS)
7.4.6 PrognosDx Health: Developing Epigenetic Prognostics
8. Research and Product Development Strategies in Epigenetics 2014
8.1 Epigenetics Therapies, Technologies and Diagnostics Market by Disease 2014-2024
8.2 Present and Future Epigenetic Research in Cancer
8.2.1 Twin Studies Reveal Epigenetic Biomarkers in Breast Cancer
8.2.2 Colorectal Cancer: More Than Two Biomarkers Established
8.2.3 Lung Cancer: Prognostic Markers
8.2.4 Prostate Cancer: The Need for Progression in Epigenetic Therapies
8.3 The Role of DNA Hypomethylation in Autoimmune Diseases
8.3.1 Lupus
8.3.2 Rheumatoid Arthritis as a Target for Drugs and Diagnostics
8.3.2.1 Ignyta: Pioneer in Epigenetic Diagnostic for Rheumatoid Arthritis
8.3.3 Prevalence of Diabetes linked to Diet and Ageing
8.4 Neurodegenerative Diseases
8.4.1 Alzheimer’s Disease: Symptoms Improved with HDAC Inhibitors
8.4.2 Huntington’s Disease: Epigenetic Drugs in Clinical Development
8.5 Neurological Disorders
8.5.1 Drug Resistance in Schizophrenia
8.5.2 Hundreds of Genetic and Epigenetic Mutations linked to Autism
8.6 New Epigenetic Therapy Targets
8.6.1 BET Proteins Targeted by Multiple Therapeutic Areas
8.6.2 Importance of DNA Hydroxymethylation
8.6.3 Sirtuins: Undergoing Limited Research
8.6.4 Histone Methyltranferase
8.6.4.1 Lysine Methyltranferase
8.6.4.2 Domainex: Development of HMT Inhibitor
8.6.4.3 Protein Arginine Methyltransferases: The Need for Improved Potency
8.6.4.4 Lysine Demethylases: Potential Cancer Treatment Target
9. Epigenetic Therapies, Diagnostics and Related Technologies: Industry and Market Trends 2014-2024
9.1 Epigenetic Therapies, Technologies and Diagnostics: Strengths and Weaknesses 2014-2024
9.1.1 Understanding Epigenetic Markers and Mechanisms
9.1.2 Specificity of Marketed Epigenetic Therapies
9.2 Epigenetics Therapies, Technologies and Diagnostics Market Opportunities and Threats 2014-2024
9.2.1 The Important Role of Translational Research
9.2.2 Development of Companion Diagnostics in Conjunction with Therapies
9.2.3 Rich Therapeutic and Diagnostic Pipelines
9.2.4 Combination Therapy with Epigenetic Drugs Show Promise
9.2.5 Epigenetic Drugs to Succeed Drug Resistance
9.2.6 Therapy Target Scope besides HDAC and DNMT Inhibition
9.3 Epigenetics Therapies, Technologies and Diagnostics: STEP Analysis 2014-2024
9.4 Social Factors Affecting Epigenetic Product Development
9.4.1 The Influence of Environment
9.4.2 The Role of Epigenetics in Ageing and Diseases
9.4.2.1 Increasing Prevalence of Global Disease to Drive Epigenetics Market Growth
9.4.3 Targeting Orphan Diseases and Patient Subpopulations
9.4.4 Use of Epigenetics in Personalised and Stratified Medicine
9.5 Advancing Epigenetic Technologies to Support Epigenetic Research
9.5.1 NGS: Improving the Quality of Epigenetic Research
9.5.2 Epigenetics to Help Drive Stem Cell Research Development
9.5.3 Complementary and Competing Forces
9.5.3.1 Genomics
9.5.3.2 Proteomics
9.5.3.3 Metabolomics
9.6 Economic Factors
9.6.1 Recent Developments Helped Reduce Costs in Epigenetic Research
9.6.2 Importance of Big Pharma in Epigenetic Markets 2014-2024
9.6.2.1 Pfizer
9.6.2.2 Novartis
9.6.2.3 GSK: Part of Multiple Agreements in Epigenetics
9.6.3 Valuable Licensing Deals in Epigenetics
9.6.4 Epigenetic Business Models
9.7 Political Issues
9.7.1 Ethics in Epigenetic Research
9.7.2 Global Collaboration to Expedite Market Growth
9.7.2.1 Structural Genome Consortium
9.7.2.2 Roadmap Epigenomics Project (NIH)
9.7.2.3 International Human Epigenome Consortium
9.7.2.4 Blueprint Project
10. Research Interview
10.1 Interview with Dr Eric Marcotte, Strategic Lead, Canadian Epigenetics, Environment and Health Research Consortium (CEEHRC)
10.1.1 Canadian Institute of Health Research: Interest in Epigenetics
10.1.2 Canadian Epigenetic Therapy Market
10.1.3 Prominent Epigenetic Therapeutic Areas in the Future
10.1.4 Promising New Epigenetic Therapy and Diagnostics
10.1.5 Future of Canadian Epigenetics Market
10.1.6 CIHR and JST Partnership Outcome
11. Conclusions from the Research and Analysis
11.1 Therapies Submarket Accounts for Most of the Epigenetic Market Revenues in 2013
11.2 Growth Expected in All Submarkets of the Epigenetic Market 2014-2024
11.2.1 Developed National Pharma Markets to Lead, 2014-2024
11.3 Many Opportunities Exist in the Epigenetics Industry and Market
List of Tables
Table 1.1 Global Epigenetics Market Forecast: Market Size ($m), AGR (%) and CAGR (%) by Region, 2013-2024
Table 2.1 Selected Enzymes Involved in Epigenetics
Table 2.2 Selected Treatments for MDS, 2013
Table 3.1 Epigenetic Therapies, Technologies and Diagnostics Sector: Global Market Size ($m) and Market Share (%), 2013
Table 3.2 Epigenetic Therapies, Technologies and Diagnostics: Market Size ($m), AGR (%) and CAGR (%) Forecast, 2013-2024
Table 3.3 Epigenetic Therapies, Technologies and Diagnostics: Submarket Shares (%), 2013-2024
Table 3.4 Epigenetic Therapies Submarket by Drug: Market Size ($m) and Market Share (%), 2013
Table 3.5 Epigenetic Therapies Submarket: Market Size ($m), AGR (%) and CAGR (%) Forecasts by Drug, 2013-2024
Table 3.6 Epigenetic Technologies Submarket: Global Market Size ($m) Forecast, 2013-2024
Table 3.7 Epigenetic Diagnostics Submarket: Global Market Size ($m) Forecast, 2013-2024
Table 4.1 Epigenetic Therapies, Technologies and Diagnostics: Market Size ($m) and Market Share (%) by Region, 2013
Table 4.2 Global Epigenetic Market Forecast: Market Size ($m), AGR (%) and CAGR (%) by Region, 2013-2024
Table 4.3 Epigenetic Therapies, Technologies and Diagnostics: Market Share (%) by Region, 2013-2024
Table 4.4 Epigenetic Therapies, Technologies and Diagnostics: US Market Size ($m) Forecast, 2013-2024
Table 4.5 Epigenetic Therapies, Technologies and Diagnostics: Canadian Market Size ($m) Forecast, 2013-2024
Table 4.6 Epigenetic Therapies, Technologies and Diagnostics: EU Market Size ($m) and Market Share (%) by Leading Country, 2013
Table 4.7 Selected Epigenetics Companies with Headquarters in the EU, 2013
Table 4.8 Epigenetic Therapies, Technologies and Diagnostics: EU Market Size ($m) Forecast, 2013-2024
Table 4.9 EU Epigenetics Therapies, Technologies and Diagnostics Market: Market Size ($m) Forecasts by Leading Country, 2013-2024
Table 4.10 Epigenetic Therapies, Technologies and Diagnostics: German Market Size ($m) Forecast, 2013-2024
Table 4.11 Epigenetic Therapies, Technologies and Diagnostics: UK Market Size ($m) Forecast, 2013-2024
Table 4.12 Epigenetic Therapies, Technologies and Diagnostics: Japanese Market Size ($m) Forecast, 2013-2024
Table 4.13 Epigenetic Therapies, Technologies and Diagnostics: BRIC Nations (Grouped) Market Size ($m) Forecast, 2013-2024
Table 5.1 Epigenetic Therapies Submarket: Submarket Shares (%) by Drug, 2013-2024
Table 5.2 Vidaza: Historical Revenue ($m), AGR (%) and CAGR (%), 2004-2013
Table 5.3 Vidaza: Revenue ($m) by Region, H2 2012-2013
Table 5.4 Celgene Sponsored Trials of Oral Vidaza (azacitidine), 2013
Table 5.5 Selected Late-Stage Clinical Trials of Vidaza (azacitidine), 2013
Table 5.6 Vidaza Revenue ($m) Forecast, AGR (%) and CAGR (%), 2013-2024
Table 5.7 Dacogen: Historical Revenue ($m), Royalty Revenue ($m), AGR (%) and CAGR (%), 2006-2012
Table 5.8 Late-Stage Clinical Trials of Dacogen (decitabine), 2013
Table 5.9 Dacogen Revenue ($m) Forecast, AGR (%) and CAGR (%), 2013-2024
Table 5.10 Multiple Myeloma Prevalence by Region, 2013
Table 5.11 Selected Late-Stage Clinical Trials of Zolinza (vorinostat), 2013
Table 5.12 Zolinza: Revenue ($m) Forecast, AGR (%) and CAGR (%), 2013-2024
Table 5.13 Istodax: Historical Revenue ($m), AGR (%) and CAGR (%), 2010-2013
Table 5.14 Phase III Clinical Trials of Istodax (romidepsin), 2013
Table 5.15 Istodax: Revenue ($m) Forecast, AGR (%) and CAGR (%), 2013-2024
Table 5.16 Selected HDAC Inhibitors in Development, 2013
Table 5.17 TopoTarget/ Spectrum Pharmaceuticals Sponsored Clinical Trials of Beleodaq (belinostat), 2013
Table 5.18 Beleodaq: Revenue ($m) Forecast, AGR (%) and CAGR (%), 2015-2024
Table 5.19 Clinical Trials of Faridak (panobinostat), 2013
Table 5.20 Faridak: Revenue ($m) Forecast, AGR (%) and CAGR (%), 2015-2024
Table 5.21 Clinical Trials of Entinostat in Breast Cancer and Lung Cancer, 2013
Table 5.22 Drug Mechanisms Being Assessed in Clinical Trials for Breast Cancer and Multiple Myeloma, 2012
Table 5.23 Clinical Trials of Resminostat (4SC-201), 2013
Table 5.24 Clinical Trials of Pracinostat, 2013
Table 5.25 Clinical Trials of Rocilinostat (ACY-1215), 2013
Table 5.26 Clinical Trials of Givinostat (ITF2357), 2013
Table 5.27 Selected DNMT Inhibitors in Development, 2013
Table 5.28 Clinical Trials of SGI-110, 2013
Table 5.29 Clinical Trials of FdCyd (5-Fluoro-2’-deoxycytidine), 2013
Table 5.30 Selected Pipeline for Other Epigenetic Enzyme Inhibitors, 2013
Table 5.31 Selected MiRNA Therapy Pipeline, 2013
Table 5.32 CellCentric’s Research Institution Affiliations, 2012
Table 5.33 IkerChem Epigenetic Pipeline, 2013
Table 6.1 Fall in Average Cost ($m) of Sequencing the Human Genome, 2000-2013
Table 6.2 Advantages of Single Molecule Sequencing over Next Generation Sequencing, 2014
Table 6.3 Selected Producers of Single Molecule Sequencing Technologies, 2014
Table 6.4 Life Technologies: Revenues ($m) and AGR (%) by Sector, 2011-2012
Table 7.1 Marketed Epigenetic Colorectal Cancer Test Cost ($), Specificity (%) and Sensitivity (%) Comparison, 2013
Table 7.2 Epigenomics: Historical Revenue ($m), AGR (%) and CAGR (%), 2009-2013
Table 7.3 MDxHealth: Diagnostics Pipeline, 2013
Table 7.4 MDxHealth: Historical Revenue ($m) and CAGR (%) by Source, 2009-2013
Table 8.1 US Prevalence of Cancers Targeted by Epigenetic Therapies and Diagnostics, 2013
Table 9.1 Epigenetic Therapies, Technologies and Diagnostics Market: Strengths and Weaknesses, 2014
Table 9.2 Epigenetic Therapies, Technologies and Diagnostics Market: Opportunities and Threats, 2014-2024
Table 9.3 Epigenetic Therapies, Technologies and Diagnostics Market: STEP Analysis, 2014-2024
Table 9.4 Selected Licensing Deals for Epigenetic Therapies, 2011-2014
Table 9.5 Selected University Spin-Outs in the Epigenetics Industry, 1997-2011
Table 9.6 IHEC Member Organisations, 2013
Table 11.1 Epigenetic Market Size ($m), Market Share (%) and CAGR (%) by Submarket, 2013, 2018 and 2024
Table 11.2 Epigenetic Therapies, Technologies and Diagnostics Market Size ($m), Market Share (%) and CAGR (%) by Region, 2013, 2018 and 2024
List of Figures
Figure 1.1 Prevalence of Cancers Targeted by Epigenetic Therapies and Diagnostics, 2013
Figure 1.2 Global Epigenetics Market Segmentation, 2014
Figure 2.1 Stages of Cutaneous T Cell Lymphoma
Figure 2.2 Chromatin Immunoprecipitation (chIP) Process
Figure 3.1 Epigenetic Therapies, Technologies and Diagnostics Sector: Global Market Share (%), 2013
Figure 3.2 Epigenetic Therapies, Technologies and Diagnostics: Market Size ($m) Forecast, 2013-2024
Figure 3.3 Epigenetic Therapies, Technologies and Diagnostics Market: Drivers and Restraints, 2014-2024
Figure 3.4 Epigenetic Therapies, Technologies and Diagnostics: Submarket Shares (%), 2018
Figure 3.5 Epigenetic Therapies, Technologies and Diagnostics Submarket Shares (%), 2024
Figure 3.6 Epigenetic Therapies Submarket by Drug: Global Market Share (%), 2013
Figure 3.7 Epigenetic Therapies Submarket: Global Market Size ($m) Forecast, 2013-2024
Figure 3.8 Epigenetic Therapies Submarket: Drivers and Restraints, 2014-2024
Figure 3.9 Epigenetic Technologies Submarket: Global Market Size ($m) Forecast, 2013-2024
Figure 3.10 Epigenetic Technologies Submarket: Drivers and Restraints, 2014-2024
Figure 3.11 Epigenetic Diagnostics Submarket: Global Market Size ($m) Forecast, 2013-2024
Figure 3.12 Epigenetic Diagnostics Submarket: Drivers and Restraints, 2014-2024
Figure 4.1 Epigenetic Therapies, Technologies and Diagnostics: Market Share (%) by Region, 2013
Figure 4.2 Epigenetic Therapies, Technologies and Diagnostics in Developed National Markets: Drivers and Restraints, 2014-2024
Figure 4.3 Epigenetic Therapies, Technologies and Diagnostics in Emerging National Markets: Drivers and Restraints, 2014-2024
Figure 4.4 Epigenetic Therapies, Technologies and Diagnostics Market Share (%) by Region, 2018
Figure 4.5 Epigenetic Therapies, Technologies and Diagnostics Market Share (%) by Region, 2024
Figure 4.6 Epigenetic Therapies, Technologies and Diagnostics: US Market Size ($m) Forecast, 2013-2024
Figure 4.7 Epigenetic Therapies, Technologies and Diagnostics: Canadian Market Size ($m) Forecast, 2013-2024
Figure 4.8 Epigenetics Therapies, Technologies and Diagnostics: EU Market Share (%) by Leading Country, 2013
Figure 4.9 Epigenetic Therapies, Technologies and Diagnostics: EU Market Size ($m) Forecast, 2013-2024
Figure 4.10 Epigenetics Therapies, Technologies and Diagnostics: French, Spanish and Italian Market Size ($m) Forecasts, 2013-2024
Figure 4.11 Epigenetic Therapies, Technologies and Diagnostics: German Market Size ($m) Forecast, 2013-2024
Figure 4.12 Epigenetic Therapies, Technologies and Diagnostics: UK Market Size ($m) Forecast, 2013-2024
Figure 4.13 Epigenetics Therapies, Technologies and Diagnostics: Japanese Market Size ($m) Forecast, 2013-2024
Figure 4.14 Epigenetics Therapies, Technologies and Diagnostics: BRIC Nations (Grouped) Market Size ($m) Forecast, 2013-2024
Figure 5.1 Epigenetic Therapies Submarket: Submarket Shares (%) by Drug, 2018
Figure 5.2 Epigenetic Therapies Submarket: Submarket Shares (%) by Drug, 2024
Figure 5.3 Vidaza: Historical Revenue ($m) and AGR (%), 2004-2013
Figure 5.4 Vidaza: Revenue ($m) by Region, H2 2012-2013
Figure 5.5 Vidaza Revenue ($m) Forecast, 2013-2024
Figure 5.6 Vidaza Revenue: Drivers and Restraints, 2014-2024
Figure 5.7 Vidaza and Dacogen: Chemical Structures
Figure 5.8 Dacogen: Historical Revenue ($m) and Royalty Revenue ($m), 2006-2012
Figure 5.9 Dacogen Revenue ($m) Forecast, 2013-2024
Figure 5.10 Dacogen Revenue: Drivers and Restraints, 2014-2024
Figure 5.11 Zolinza: Revenue ($m) Forecast, 2013-2024
Figure 5.12 Zolinza Revenue: Drivers and Restraints, 2014-2024
Figure 5.13 Istodax: Historical Revenue ($m) and AGR (%), 2010-2013
Figure 5.14 Istodax: Revenue ($m) Forecast, 2013-2024
Figure 5.15 Istodax Revenue: Drivers and Restraints, 2014-2024
Figure 5.16 HDAC Inhibitor Expected Approvals, 2015-2020
Figure 5.17 Beleodaq: Revenue ($m) Forecast, 2015-2024
Figure 5.18 Faridak: Revenue ($m) Forecast, 2015-2024
Figure 5.19 Drug Mechanisms Being Assessed in Clinical Trials for Breast Cancer: Breakdown, 2012
Figure 6.1 Fall in Average Cost ($m) of Sequencing the Human Genome, 2000-2013
Figure 6.2 Life Technologies: Revenues ($m) by Sector, 2011-2012
Figure 7.1 Marketed Epigenetic Colorectal Cancer Test Cost ($), Specificity (%) and Sensitivity (%) Comparison, 2013
Figure 7.2 Epigenomics: Historical Revenue ($m) and AGR (%), 2009-2013
Figure 7.3 MDxHealth: Historical Revenue ($m) by Source, 2009-2013
Figure 8.1 Prevalence of Cancers Targeted by Epigenetic Therapies and Diagnostics, 2013
Figure 11.1 Epigenetic Market Size ($m) by Submarket, 2013, 2018 and 2024
Figure 11.2 Epigenetic Therapies, Technologies and Diagnostics Market Size ($m) by Region, 2013, 2018 and 2024
4SC
Abbott Laboratories (AbbVie)
Accelerate Brain Cancer Cure
Accium BioSciences
Acetylon Pharmaceuticals
Active Motif
Agence Nationale de la Recherche (ANR)
Agilent
American Association of Cancer Research (AACR)
American Cancer Society
American Medical Association
American Society of Clinical Oncology
American Society of Hematology
Amgen
ARUP Laboratories
Astellas Pharma
Astellas Venture Management
Astex Pharmaceuticals (Otsuka Pharmaceutical)
AstraZeneca
Aton Pharma (now part of Merck & Co.)
Australian Alliance for Epigenetics
Automation Partnership
Babraham Institute
Baxter
Bayer
BGI
BioAlliance Pharma SA
BioChain
Biogen Idec
BioMarin Pharmaceuticals
BioSeek
Biotech Research and Innovation Centre
Biotechnology and Biological Sciences Research Council
BLUEPRINT Epigenome Consortium
Boehringer Mannheim
Bristol-Meyers Squibb
Bundesministerium für Bildung und Forschung (BMBF)
Cambridge Institute for Medical Research
Cambridge University
Canadian Epigenetics, Environment and Health Research Consortium (CEEHRC)
Canadian Institute for Health Research (CIHR)
CanAm Bioresearch
Cancer Research Technology
Cancer Research UK
Celgene
CellCentric
Celleron Therapeutics
Cellzome
Center for Genomic Sciences (CGS)
Centre for Addiction and Mental Health (Canada)
Centre for Cancer Research
Centre for Genomic Regulation (Barcelona)
Centre National de la Recherche Scientifique (CNRS)
Ceptaris Therapeutics
ChemRar High Tech Center
Chiron
Chroma Therapeutics
City of Hope Medical Centre
Clavis Pharma
Committee for Medicinal Products for Human Use (CHMP)
Constellation Pharmaceuticals
Cornell University
CURELUNG
Curis
Cyclacel Pharmaceuticals
Dana-Farber Cancer Institute
Diagenode
DiscoveRX
Domainex
Dr. Reddy’s Laboratories
Durviz
Eastern Cooperative Oncology Group
ECOG-ACRIN Cancer Research Group
Eisai
Eli Lilly
Elixir Pharmaceuticals
EMD Millipore (also known as Merck Millipore)
EnVivo Pharmaceuticals (now part of Forum Pharmaceuticals)
EpigenDx
EpiGeneSys
Epigenetics Dream Team
Epigenomics
Epigentek
Epiontis
EpiTherapeutics
Epizyme
e-Therapeutics
European Commission (EC)
European Institute of Oncology (IEO)
European Medicines Agency (EMA)
European Patent Office
Exact Sciences
Experimental Cancer Medicine Network (ECMC)
FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee
Federal Ministry of Education and Research (BMBF)
FIRC Institute of Molecular Oncology Foundation (IFOM)
Flagship Biosciences
Forum Pharmaceuticals
Fresenius Kabi
Friedreich’s Ataxia Research Alliance (FARA)
Genentech
Genpathway
German Cancer Research Center
GlaxoSmithKline (GSK)
Gloucester Pharmaceuticals (now part of Celgene)
Go FAR (Friedreich’s Ataxia Research)
Harvard University
Health Canada
Health Genomics
Heptares Therapeutics
Hospital of Soochow University
Howard Hughes Medical Institute
Ignyta
IkerChem
Imperial College London
Indian Institute of Science Education and Research
Institute of Cancer Research
International Human Epigenome Consortium (IHEC)
Italfarmaco
Italian Institute of Technology (IIT)
Ivax LLC
Janssen Cilag
Janssen Pharmaceutica NV
Japan Science and Technology Agency (JST)
Japanese Society for Epigenetics
Jian-Xian Janssen Pharmaceuticals Ltd.
Johns Hopkins University
Kainos Medicine
Karus Therapeutics
Kindstar
King’s College London
Krembil Family Epigenetics Laboratory
Kyowa Hakko Kirin Pharma Inc.
LabCorp
Leukemia & Lymphoma Society
Life Technologies’ (now part of Thermo Fisher Scientific)
Louis Pasteur University of Strasbourg
Lundbeckfond Ventures
M.D. Anderson Cancer Center
Massachusetts General Hospital
Mayo Clinic
McGill University
MDxHealth
Medical Research Council
MEI Pharma
Memorial Sloan-Kettering Cancer Center
Merck & Co.
Merck KGaA
Merck Serono Ventures
MethylGene
MGI Pharma
Michael J. Fox Foundation for Parkinson’s Research
Microgenics
Millennium Pharmaceuticals
MIMR-PHI Institute of Medical Research
Ministry of Health, Labour and Welfare (MHLW)
Mirati Therapeutics
MiReven
Mirna Therapeutics
Mitomics
Mount Sinai Medical Center
Multiple Myeloma Research Foundation
Muscular Dystrophy Association (MDA)
Myeloma UK
Myriad Genetics
National Ataxia Foundation (NAF)
National Cancer Institute
National Comprehensive Cancer Network (NCCN)
National Council of Science and Technology
National Health and Medical Research Council (NHMRC)
National Health Service (NHS, UK)
National Institute for Health and Clinical Excellence (NICE, UK)
National Institute for Mental Health
National Institute of Allergy and Infectious Disease (NIAID)
National Institute of Cancerología
National Institute of Health, Korea
National Institute of Mental Health
National Institutes of Health (NIH)
National Institutes of Health Clinical Center (CC)
NewVac
NIH Epigenomics Roadmap Project
Nippon Shinyaku
Nottingham University
Novartis
Novartis Institutes for BioMedical Research (NIBR)
Novo Nordisk
Nycomed
Odyssey Molecular
OncoMethylome (now MDxHealth)
Onxeo
Onyx Pharmaceuticals
Orion Genomics
Oryzon Genomics
Otsuka Pharmaceuticals
Oxford University
Oxford University Hospitals NHS Trust
Pacific Biosciences
Pfizer
Pharmacyclics
Pharmion by Pharmacia & Upjohn
Physician’s Choice Laboratory Services
PLUS Diagnostics
Polymedco
Predictive Biosciences
PrognosDx Health
Project Management Agency with German Aerospace Center (PT-DLR)
Psicofarma S.A. de C.V.
Qiagen
Quest Diagnostics
Quest Laboratory
Regulus Therapeutics
Repligen
Resverlogix
Rexahn Pharmaceuticals
Roche
Roche's Translational Clinical Research Centre
Roswell Park Cancer Institute
S*BIO
SABiosciences
Salarius Pharmaceuticals
Sandoz
Sanofi
Santaris Pharma AS
Scottish Medicines Consortium (SMC)
Seattle Genetics Inc
Seed Capital
Servier
Shape Pharmaceuticals
Sidney Kimmel Comprehensive Cancer Centre
Siena Biotech
Sigma-Aldrich
Spectrum Pharmaceuticals
Structural Genomics Consortium (SGC)
Swiss Life
SwitchGear Genomics
Syndax Pharmaceuticals
Sysmex
Taiho Pharmaceutical
Takeda Pharmaceutical Company
Tempero Pharmaceuticals
Tensha Therapeutics
TetraLogic Pharmaceuticals
Teva Pharmaceutical Industries
The Lymphoma Academic Research Organisation
Thermo Fisher Scientific
Thomas Jefferson University
TopoTarget
UK Funders Alliance
UK Technology Strategy Board
United States District Court
University College London (UCL)
University of Birmingham
University of California, Los Angeles (UCLA)
University of Chicago
University of Leeds
University of North Carolina
University of the Basque Country
University of Toronto
University of Edinburgh
US Food and Drug Administration (FDA)
US National Cancer Institute
Ventana Medical Systems
Warnex
Wellcome Trust
Wistar Institute
World Health Organization (WHO)
Yakult Honsha Co.
ZoBio
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
